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Mitral Valve Prolapse (MVP) is one of the most common cardiac diseases affecting 
1 in 40 individuals worldwide. Functionally, MVP is the abnormal billowing of one or both 
of the mitral valve leaflets into the left atrium during ventricular systole. Structurally, the 
valves experience an accumulation of proteoglycans, an increase of collagen and 
hyperplasia. An echocardiogram can be used to diagnose the disease as well as determine 
the severity of it. MVP can cause several underlying effects such as regurgitation, 
arrhythmias and even sudden cardiac death in severe cases.  Although there is very little 
known about the cause of the disease, recent discoveries have identified various genetic 
associations with MVP. This is the basis by which we structure this proposal. 
A linkage analysis was conducted on a large family with non-syndromic MVP to 
find a common cause for the disease. Through this linkage analysis a specific region of 
genes was identified, in particular, a cilia gene, DZIP1 was found along with the point 
mutation in the gene. Through expression, knockout studies and biochemical approaches 
we have gained a better understanding of what DZIP1 and the mutation of DZIP1S14R/+ are 
doing during cardiac development. Currently, little is known about how mutations in the 
cilia gene can influence the development of MVP. To address this question, a two-hybrid 
screening was completed, in which DZIP1 wild type plasmid and mutant DZIP1 plasmid 
were used to determine DZIP1’s binding partners.  
 x 
A pre-mRNA processing factor protein named Prpf8, which is a fundamental 
component of the spliceosome, was found to interact with the wild type DZIP1 plasmid but 
was the only protein found to not interact with the mutant DZIP1 plasmid. Additionally, 
the previous GWAS completed on patients with MVP identified a single nucleotide 
polymorphism (SNP) in close proximity to the PRPF8 locus, which led us to hypothesize 
that this SNP could function as an enhancer to regulate Prpf8 expression. Here we present 
data that shows that Prpf8 is expressed in the mitral valves at various embryonic and 
postnatal stages, and that it co-localizes with DZIP1. Verification of the two-hybrid 
screening result was tested through co-immunoprecipitation from protein collected from 
wild type (Dzip1+/+) and mutant (Dzip1S14R/+) adult mouse tail fibroblasts. 
Furthermore, through collaborators at INSERM, chromatin conformation capture 
experiments on chromosome 17 (where PRPF8 is located) determined four potential 
regulatory sequences that are in close proximity to PRPF8’s transcription start site. With 
the given data, luciferase assays indicated sequences with enhancer function. The studies 
presented will establish a broad mechanism by which DZIP1 mutations regulate RNA 

































The heart marks the center of the circulatory system. It is comprised of four 
chambers: the left atrium, right atrium, left ventricle and the right ventricle. Each 
component of the heart plays an important role in governing how efficiently blood flows 
through it to keep a living organism alive and well. The left and the right side of the heart 
have their own pumping systems but communicate effectively. The right atrium is 
responsible for receiving deoxygenated blood from the body and pumps it to the right 
ventricle through the tricuspid valve. The right ventricle then pumps the deoxygenated 
blood to the lungs through the pulmonary valve.  In contrast, the left atrium receives the 
oxygenated blood from the lungs and pumps it to the left ventricle through the mitral 
valve. Finally, the left ventricle pumps the oxygen-rich blood through the aortic valve out 
to the rest of the body (Buckberg, Nanda, Nguyen, & Kocica, 2018).  
Our lab is interested in heart development and how improper heart development 
can lead to cardiac disease in a patient’s life. More specifically, we focus on cardiac 
valve development. As mentioned earlier there are four valves within the heart: the 
pulmonary valve, the aortic valve, the tricuspid valve and the mitral valve. All serve to 
promote unidirectional blood flow throughout the heart. If there is any disruption to this 
process, for example, incorrect valve development, this can lead to valve disease like 
mitral valve prolapse. My research aims to establish a mechanism by which the heart 
disease, mitral valve prolapse begins. This is pertinent to recent studies because it also 
provides a starting point for understanding the fundamental molecular and developmental 
processes that can be applied to the disease in general. The following chapters will 
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address our recent developmental, genetic, and molecular discoveries behind valvular 
development and mitral valve prolapse.  






















Figure 1.1 The Gross Anatomy of the Human Heart. The human heart is comprised of four 
chambers: the left atrium, right atrium, left ventricle and the right ventricle. The left and the right 
side of the heart have their own pumping systems. The right atrium receives deoxygenated blood 
from the body and pumps it to the right ventricle through the tricuspid valve. The right ventricle 
then pumps the deoxygenated blood to the lungs through the pulmonary valve.  The left atrium 
receives the oxygenated blood from the lungs and pumps it to the left ventricle through the mitral 
valve. The left ventricle pumps the oxygen-rich blood through the aortic valve out to the rest of 





The human heart consists of four chambers (right atrium, right ventricle, left 
atrium and left ventricle), and four valves (aortic and pulmonic semilunar (SL), mitral 
and tricuspid valves). For the purpose of this study, we focus on the mitral valve leaflets. 
The mitral valve leaflets are positioned directly between the left atrium and the left 
ventricle. The structure of the leaflets, plays an important role for proper function. 
(Figure 1.1). The valves work together to maintain unidirectional blood flow throughout 
the heart and are responsible for opening and closing over 100,000 times a day. (Horne et 
al., 2015). The mitral valve leaflets are enclosed with endocardial endothelial cells, while 
the remaining volume of the leaflet is made up of valvular interstitial cells (VICs) 
(Hinton et al., 2006; Rabkin-Aikawa, Farber, Aikawa, & Schoen, 2004) 
Valve development initiates from a cardiac tube that is comprised of myocardium 
and endocardium.  Between these two cell layers is a region called the cardiac jelly which 
is comprised of space-filling proteoglycans (Person, Klewer, & Runyan, 2005). The 
myocardium secretes various growth factors which induce the endothelium to undergo 
endothelial-to-mesenchymal transformation (EMT).  This results in the cardiac jelly 
being invaded by mesenchyme to initiate the first phases of valve development. This 
process is extremely crucial in defining correct valve formation. As the valves continue to 
grow and stretch further into the left ventricle, the fibrous leaflets become thinner, 
increasing the extracellular matrix (ECM) deposition and remodeling. It is not until days 
after the birth of a newborn, that highly organized and distinct layers that represent the 
ECM are seen. The ECM of the valve is composed of three stratified layers that are rich 
in collagens, proteoglycans and elastin. Both mouse and human valves have these 
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boundaries although there is slight variation on how many ECM zones exist. The 
complete valve maturation and remodeling in mammals will continue into juvenile 
stages. (Combs & Yutzey, 2009). 
Over the years there have been many studies that have included the similarities 
between animal models and human anatomy, in order to make new discoveries in 
translational science. Therefore, the comparison of adult aortic valve leaflet structure and 
composition demonstrates similar stratification in humans, sheep, chickens, rabbits, and 
mice (Combs & Yutzey, 2009). The process of valve formation has certainly been 
universal over time, accommodating the species in which they reside. For example, even 
in the smallest of species we see conserved valve cell regulatory mechanisms being 
represented in Drosophila (Lammers et al., 2017). 
As we examine valve formation on a molecular level we look to evaluate the 
endocardial cushion composition and how the study of valve development includes 
different signaling mechanisms. The first studies that identified EMT in the heart were 
through pioneering work from the laboratory of Roger Markwald (Markwald, Fitzharris, 
& Manasek, 1977). When chick cardiac explants were placed on a collagen lattice, the 
endocardium was seen adopting migratory and invasive characteristics.  However, when 
the myocardium was removed from these cultures, the endocardium failed to change its 
phenotype.  This was the first evidence demonstrating that myocardial-secreted factors 
could induce an endothelial-to-mesenchymal transformation.  From these seminal studies, 
concerted efforts have focused on identifying the myocardial initiating signals (Runyan & 
Markwald, 1983). Since then, major growth factors have been identified that regulate this 
EMT process, such as transforming growth factor beta (TGFb) and basic metabolic panel 
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(BMP). Notch signaling, active in the endocardium, has also been defined as playing a 
critical role in EMT progression and can synergize with TGFb and BMP ligands 
(Garside, Chang, Karsan, & Hoodless, 2013). The endocardial-to-mesenchymal transition 
process occurs when subsets of AV (atrioventricular) and OFT (outflow tract) 
endocardial cells transform into a mesenchymal phenotype, which determines the 
anatomical placement where the valves will form within the primary heart tube (de 
Vlaming et al., 2012). 
Additionally, the process of valve development occurs in various steps. These 
steps include: the formation of the ECM, the migration of endocardial cells into the ECM, 
the event of cardiac looping that induces endocardial cushion swellings, triggering the 
overpopulation of endocardial cushions (Markwald, Fitzharris, Bolender, & Bernanke, 
1979) (Eisenberg & Markwald, 1995) and the eventually forming the stratified layers 
(proteoglycans, elastin and collagen) of the ECM (Figure 1.2). Additionally, the cause of 
the swelling results from the myocardium of specific regions of the primary heart tube, 
the AV junction and the OFT upregulates the secretion of the ECM. This process gives 
rise to cushion morphogenesis induces a subset of AV and OFT endocardial cells to lose 
their junctions and adopt a mesenchymal-like phenotype as they migrate into the cardiac 
jelly (Person et al., 2005). Furthermore, there have been studies that state the role that 
both myocardial and endocardial- derived signaling pathways affect endocardial cushion 
EMT and proliferation of valve progenitor cells (de Lange et al., 2004). Eventually, this 















Figure 1.2 Myxomatous Degeneration in Valves. Human posterior leaflets of control 
and DCHS1 p.R2330C were isolated, fixed and stained with Movats Pentachrome. 
Leaflet thickening, elongation and myxomatous degeneration is observed in the DCHS1 
p.R2330C leaflet compared to control. Expansion of the proteoglycan layer (blue) and 
disruption of the normal stratification of matrix boundaries is observed in DCHS1 
p.R2330C leaflets. Blue=proteoglycan, Yellow=collagen, Black=elastin, Red=fibrin or 




Cell Types in the Mature Mitral Valve 
Through the previous events of valve development, the valve becomes mature and 
has its own different cell types. There are two main cell types that make up the valves. 
Those are the valvular interstitial cells (VICs) and the valvular endothelial cells (VECs). 
The VEC’s reside on the outer rim of the leaflets, creating a border for the valve. It has 
been shown that any infiltration or breakage of this border can lead to valve disease 
(Butcher & Nerem, 2007) (Leask, Jain, & Butany, 2003), (Butcher & Markwald, 2007) 
(El-Hamamsy et al., 2009). 
The majority of each leaflet is composed of VIC’s. Their fibroblastic consistency 
aids in several different characteristics throughout the valve, due to their various 
placements within the leaflets (Horne et al., 2015). The VIC’s essentially act as first 
responders: if given enough stress they have the capability of migrating and contracting, 
rather than staying in their resting state. Their main role is to mediate and maintain the 
ECM structure, throughout the maturation of valve development. Any disturbances in the 
roles of either of these cell types can lead to unfavorable consequences that can affect the 
biomechanical functions leading to diseases. The overall progression of valve 
development has many evolving steps and, in any event, if there is a misstep in the 
process there will be severe complications.  
Biomechanical Influences 
As the valve is undergoing maturation, additional factors can play a role on how 
the valves are able to perform their job accurately, for example biomechanical forces. In a 
fully developed heart the act of blood flowing from the atrium to the ventricle represents 
blood going from an area with low pressure to an area that is high in pressure. Previous 
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studies have stated that the biomechanical forces behind effectively beating the heart 
during valve development influence the formation and matrix composition of the valves  
(Butcher, McQuinn, Sedmera, Turner, & Markwald, 2007). Specifically, during 
isovolumetric relaxation, which is an interval in the cardiac cycle, the pressure difference 
between the left atrium and the left ventricle causes the MV leaflets to open and allow 
blood to flow from the left atrium into the left ventricle during diastole (Giovanni et al., 
2017). During this time the left ventricle stays in a relaxed state, allowing it to maintain a 
positive transmitral pressure and aids in filling the ventricle without complications. Soon 
after active ventricular relaxation, the fluid begins its deceleration and the MV partially 
closes, preventing any backflow of blood into the atrium (Sagie et al., 1994).  
Additionally, the leaflets of the mitral valve are connected to tendinous chords, 
which attach to the left ventricular myocardium through the papillary muscle. These 
fibrous structures provide tension to the mitral leaflets, this along with several other 
mechanical systems at play keep the tissues from ballooning upward into the left atrium 
during ventricular systole. Furthermore, in vitro models have suggested that vortices, the 
region of blood that is fixed around an axis line, is crucial to the closing of the valve. 
These vortices are generated by ventricular filling and aid the partial closure of the MV 
following early diastole and are essential for the closing of the valve. Without these 
vortices, the valve would not be able to close during ventricular contraction (Bellhouse & 
Reid, 1969).  
Developmental Basis of Disease 
As a basis to start investigating valve disease, researchers have designed many 
studies surrounding genetic disorders found in large families and from previous work 
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published on the matter. It has been stated that scientists find similarities in diseases like 
Alzheimer’s and diabetes because of the similar genetic anomalies surrounding these 
diseases and valve disease. In each instance there are gene mutations, these mutations are 
present at conception, this leads to inheritable traits passed from generation to generation 
in families and the diagnosis of these diseases appearing later in life. Identifying the 
genes and their function in familial disease is vital in understanding how mutations of 
these genes lead to disease. With mitral dystrophies, individuals in a family can show a 
high degree of variation in when they are diagnosed with the disease, despite the fact that 
the affected individuals all carry the same mutation. It has been found that children with 
clinically relevant mitral valve prolapse (MVP) have been diagnosed as young as six 
years of age. In these families, mutations in the Filamin-A  result in familial cardiac 
valvular dystrophy (Kyndt et al., 1998). Furthermore, this knowledge proposes that a 
patient’s genetic makeup accompanied with genetic variants that are present at the time 
of valvulogenesis, could dictate the severity of the valve disease. This knowledge is key 
in investigating the complexity behind valve disease, as it could open the door for new 
therapeutic aids and the discovery of associated pathways that are required for proper 
valve development.  
Mitral Valve Prolapse 
MVP is the most common form of cardiac valve disease and is a major health 
burden. The disease is characterized by the abnormal billowing of one or both of the 
mitral valve leaflets. Structurally the disease causes myxomatous degeneration and the 
valves experience an increase in proteoglycan accumulation, fragmented collagen and 
hyperplasia. This phenotype prevents the valve from functioning properly. This also 
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causes an imbalance of biomechanical forces that affects the correct positioning of the 
leaflets as well.  
 This disease affects 1 in 40 people worldwide, making its prevalence rate 
between 2-3%. Based on this information, MVP is expected to afflict approximately 176 
million people worldwide (Devereux et al., 1987). These staggering numbers have 
brought much needed attention to this disease, yet there are many factors surrounding 
MVP that are unknown. The term, MVP was coined Barlow in 1963 (Barlow & Pocock, 
1963) when he detected mitral regurgitation in the one of his patients when examining 
their heart through an angiography. MVP carries a significant burden of morbidity and 
mortality. There are no effective nonsurgical treatments for MVP and an incomplete 
understanding of its fundamental causes has hindered therapeutic efforts. While surgical 
techniques continue to improve, the number of surgical cases and associated mortality 
rates are increasing. Surgeries for degenerative mitral valve disease increased by more 
than 44% from 2011-2016 and, currently >90,000 mitral valve surgeries occur each year 
making it the fastest growing cardiovascular intervention in the United States (Coutinho 
& Antunes, 2017). MVP can lead to arrhythmias, heart failure, and even sudden cardiac 
death and 1 in 10 patients will require valve surgery. Through various studies it was 
found that MVP could be inheritable or naturally irregular, but the initial diagnosis of 
MVP left many patients undetected. 
The Framingham Heart study detailed vital information found in the 
echocardiography of MVP patients.  It was found that echocardiographers misinterpreted 
the phenotype because positioning of echo probe did not relay proper mitral valve 
geometry (Freed et al., 1999). Initially, the physicians were doing an apical view to 
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obtain the correct orientation of the valve. Yet, when probe was turned there was accurate 
representation of the myxomatous valve. Through this study physicians were able to 
develop a more efficient and precise way to diagnosis MVP patients and also detect 
accompanying health defects with this disease like heart failure and atrial fibrillation.  
Recent genetic studies by our group have provided new hope in identifying MVP 
disease mechanisms, as we were the first to describe genetic causes for non-syndromic 
MVP (Durst et al., 2015) (Dina et al., 2015) (Figure 1.3). Furthermore, through these 
genetic studies our lab has linked primary cilia with MVP (Durst et al., 2015) (Dina et al., 
2015). In this study we have used this information to develop testable hypotheses that 






















Table 1.1: Genes associated with MVP. Genetic anomalies associated with mitral valve 
prolapse in humans. (Durst et al., 2015) (Dina et al., 2015) (Kyndt et al., 1998) (Le 
Tourneau et al., 2018). 
 
Table 1.1 Genetic associations with mitral valve prolapse in humans  
 Gene or chromosome Defect 
localization/mechanism/Phenotype 
Non-syndromic MVP   
• Filamin A-MVD FLNA Mechanotransduction/ Cardiac 
valvular dystrophy 
• Myxomatous disease 
(MMVP2) 
DCHS1 Cell Migration and polarity/ Dchs1 
mutations = MVP 
• Myxomatous disease 
(MMVP1-3) 
Chr 16-13 -- 
Frequent Variants 
    GWAS 
LMCD1 Transcription factor/ Knockdown of 
LMCD1 in mice= valve 
regurgitation  
 TNS1 Focal adhesion protein/cytoskeleton 
organization/Tns1-/- mice= 
myxomatous degeneration in 













Cilia as a Focus 
Due to our genetic discoveries in MVP patients that revealed a preponderance of 
mutations in cilia genes, we choose to focus on how these gene variants may affect 
ciliogenesis. Cilia are microtubule-containing structures (axonemes) that project from the 
cell. There are two main types of cilia: motile and immotile. Whereas motile cilia 
(>100/cell) are largely used to move fluid or gametes, immotile cilia (a.k.a. primary cilia) 
are solitary (typically one per cell), extend from the centriole/basal body and were 
previously thought to be vestigial evolutionary remnants with no persisting function. 
However, this traditional belief was challenged by recent genetic discoveries that linked 
mutations in cilia genes to a spectrum of rare syndromic diseases known as ciliopathies. 
These findings spurred concerted efforts to understand ciliogenesis, their downstream 
pathways, as well as additional genetic conditions that stem from defects in cilia structure 
and/or function. MVP (Durst et al., 2015). What is emerging from these studies is that 
primary cilia function as transducers of mechanical, electrical and chemical signals in a 
tissue-specific and temporal-dependent context.  In doing so, they relay information 
regarding various growth factor signals including Hh, Wnt and Pdgfa to influence cell 
survival, differentiation, and tissue organization. How cilia are built (aka ciliogenesis) is 







Figure 1.3 Primary Cilia Governs the Signaling Pathways for the Cell. 
Primary cilia and motile cilia are essential for many common signaling pathways. Primary 
cilia exhibit a 9+0 microtubule ratio and in contrast motile cilia have a 9+2 ratio. Primary 
cilia are one per cell and act as mechanosensors of fluid flow and contribute to cell-cell 




























MVP is one of the most common cardiac diseases and it is the most common 
cardiac valvular disease. MVP can occur as part of a recognized syndrome such as 
Marfan syndrome, characterizing it as syndromic MVP, or it can occur in isolation in 
which case it is called non-syndromic MVP. Although genetic causes for some 
syndromic forms of MVP are known, the genetic underpinnings of the more common 
non-syndromic form of MVP, which affects 2-3% of the population, have remained 
elusive. MVP occurs when the mitral valve leaflets disrupt steady blood flow from the 
left atrium to the left ventricle. This happens when either one or both of the leaflets 
(posterior and anterior) balloon upward into the left atrium. 
Through the findings revealed in the Framingham Heart study, the diagnosis of 
MVP was fully understood and scientists took a closer look into the genetics behind the 
disease. In 1999, researchers performed familial screens that identified the first locus 
associated with autosomal dominant MVP, MMVP-1. The locus is on chromosome 16p 
(Disse et al., 1999) and by performing several more screens that verified the 
heterogeneity of the disease, linkage analysis mapped to two loci. This was followed by 
more studies linking MMVP2 located on chromosome 11p15.4.  
Additionally, in 2007, the gene Filamin A was found to be linked to MVP because 
the of its involvement in X-linked myxomatous valvular dystrophy (Le Tourneau et al., 
2018; Toomer et al., 2019). These studies ignited researchers to delve more into this 
finding and search for more components that are responsible for MVP in patients. We 
now have compelling genetic and functional evidence that significantly advance our 
understanding of MVP pathogenesis. The gene DCHS1 (Durst et al., 2015) is well- 
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known for its encoding of calcium-dependent cell-cell adhesion molecules. Previous 
studies within our lab found that mutations in DCHS1 cause MVP. Additionally, a 
genome-wide association study has led many scientists and healthcare professionals to 
observe genetic variants within these MVP patients (Dina et al., 2015). However, patients 
with rare syndromic diseases that stem from alterations in the structure and function of 
primary cilia (“ciliopathies”) have a higher prevalence of MVP, suggesting that primary 




Genetic studies  
To date, there has been a short list of genes that are implicated in MVP, some of 
which are: DCHS1, TNS1 and LMCD1. Specifically, DCHS1 mutations causes 
myxomatous valves and has been linked to polycystic kidney disease (PKD), which is 
another ciliopathy (Durst et al., 2015). In a previous GWAS, where 6 significant loci in 
association with MVP were found, genes TNS1 and LMCD1 showcased phenotypes 
linked to MVP. Tns1-/- mice exhibit an enlarged posterior leaflet and the knockdown of 
LMCD1 in mice led to valve regurgitation (Dina et al., 2015). The connections made 
through investigating these genetic associations would lead to more inheritable findings 
in MVP patients. 
Furthermore, we studied the pedigree of a family with non-syndromic MVP we 
began to identify crucial players involved with the disease. Using a combination of 
linkage analyses, as well as exome and capture sequencing, we recently identified loss of 
function mutations in the cilia gene, DZIP1, that segregate with mitral valve prolapse in 
multiple MVP families. Dzip1 is a centrosomal protein that is required for ciliogenesis. 
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Patients with DZIP1 missense mutations displayed autosomal dominant inheritance, 
which we have shown in multiple model systems to cause haploinsufficiency and disease 
phenotype, making DZIP1, a novel gene for mitral valve prolapse. As we begin to 
examine the connections between primary cilia and MVP we take a closer look for the 
expression of primary cilia during valve development.  
Temporal Expression of Primary Cilia Through Valve Development  
To determine whether primary cilia is expressed on the mitral valves 
immunohistochemical stains were completed, by marking the basal body (gamma 
tubulin) and the axoneme (acetylated tubulin). These stains were imaged using high-
resolution confocal microscopy. Through this application we observed the expression of 
cilia on early embryonic stages of valve development (E13.5-E15.5), specifically on the 
valvular interstitial cells (VICs). Primary cilia are noticeably absent on the valvular 
endothelial cells (VECs) and begin to digress in expression at timepoints after postnatal 
day 0 (Figure 2.1). Through examining the localization of primary cilia, we begin to 
expose their role in valvular development. 
As mentioned earlier we see an influx of primary cilia being expressed on all cells during 
early stages of development, particularly the VICs. When the ECM is beginning to form 
it is mostly composed of proteoglycans like versican and through development the 
stratified layers begin to appear. It is noted that primary cilia are more co-localized to 
areas that are rich in proteoglycans (Figure 2.2). This discovery gives insight on the 
expression pattern of primary cilia as they are seen through valve development. 
Furthermore, applying the information known about biomechanical forces being a key 
player in having proper valve development, research suggests that primary cilia are able 
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to sense the change in blood flow and adapt to this change by acting as mechanosensors 
to regulate valvulogenesis. Even though this function of primary cilia is still not fully 
understood, there have been efforts toward this possibility (Nauli et al., 2013) , each 














Figure 2.1 Localization of Primary Cilia During Mitral Valve Development. (A-F) IHC 
performed on wild type mouse heart tissue. Co-staining of the axonemes (green, acetylated a-
tubulin) and the basal bodies (red, g-tubulin) show cilia expressed on murine mitral valve interstitial 
cells but not on valve endocardial cells at these stages. Blue=Nuclei (Hoescht), AL, PL = Anterior 
and Posterior Leaflets, respectively. (G) Box plot of cilia lengths in the mitral valves showing 
growth in length during development with few cilia observed in the adult valve. The blue boxes 
show the main distribution of the cilia length values. The bottom of the box is the 25th percentile, 
the middle line is the median value, and the top of the box is the 75th percent. Red dot denotes the 
mean cilia length. Error bars represent 95% confidence intervals. *=p < 0.0001, **=p < 0.001, 
***=p < 0.01 (Image by Diana Fulmer, Norris Lab). 
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Figure 2.2 Primary Cilia Expression Co-Localized with Proteoglycans in Valve 
Development. (A) Immunohistochemistry for the ciliary axoneme (green), collagen (red, 
top) versican (red, bottom), and nuclei (blue) show expression of cilia throughout 
development. Cilia appear to be expressed highly in areas rich in proteoglycans and less in 
areas high in collagen. C= conal cushions, RC= right coronary, LC=left coronary, NC= 
non-coronary, Ao= aorta. (B) High magnification images of axonemes (green) and 
collagen/versican (red). Arrows depict collagen rich regions expressing shortened cilia. (C) 
Quantification of cilia length in both versican and collagen rich regions shows decreased 
average cilia length in collagen rich regions when compared with versican rich regions, 





A New Cilia Gene Found Linked to MVP 
 
By uncovering the expression of primary cilia and its regions of specificity on the 
mitral valve during development, we took a separate approach on investigating a 
commonality for the disease. To start, a GWAS was performed across a wide range of the 
human genome in an effort to identify genetic risk factors within the population. This 
study was followed by a sequential linkage analysis that was conducted on a large non-
syndromic family with MVP to find a commonality for this disease. Through this study 
the linkage analysis identified a specific region on chromosome 13 and among the 
different genes that were found, a cilia gene called DZIP1 was identified (Figure 2.3).  
Protein Expression of Dzip1 
DZIP1 is classified as a DAZ Interacting Zinc Finger Protein and has previously 
been implicated in a disease called Acrodermatitis Enteropathica (AE). As mutations in 
this gene has been shown to cause the inability to absorb zinc from the intestine. This can 
result in skin inflammation on various parts of the body, because there is a significant lack 
of zinc. Knowing this characteristic, we also see DZIP1 in various signaling pathways, Hh 
and signaling through GPCR and most recently we see DZIP1 required for the formation 
of cilia. Through our vast studies within the lab we were able to identify cilia as an  
organelle that played a major role in the development of the mitral valves. We discovered 
DZIP1 as a key player in our current research by evaluating several different families with 
non-syndromic MVP through GWAS (1412 MVP and 2439 controls).   
Through immunohistochemistry application the expression of Dzip1 is seen on the 
mitral valve expression patterns of Dzip1 have been seen to co-localize to the base of the 
















Figure 2.3 Identification of DZIP1 as an MVP Gene. (A) Multigenerational family with inherited, 
autosomal-dominant, non-syndromic MVP. Black circles and squares are affected individuals, green circles 
and squares are individuals who exhibit minimal MVP, white circles and squares are unaffected. 
Circles=female, squares=male. ID designations for family members are denoted under the circles or 
squares. Proband is identified with the black arrow. (B) Human transcript and marker maps of the linkage 
interval on chromosome 13. Candidate region is within 13q31.3-32.1, and all RefSeq genes and their 
orientations are shown within the 8.2-Mb interval. DZIP1, the only cilia gene within the locus, is 
highlighted in pink. (C) Sanger sequencing identified a single missense mutation within exon 5 of DZIP1 
resulting in a serine to arginine change. The mutation segregates with the affected patients and is 
designated by +/- in the pedigree. (D) Population frequency showing the rarity of the identified DZIP1 
variant in the population (Image by Dr. Russell Norris, Science Translational Medicine, Accepted 2019).  
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that is exhibited in our MVP patients could be seen in a mouse model. Therefore, a 
Dzip1S14R/+ knock-in mouse was created using CRISPR (Clustered Regularly Interspaced 
Short Palindromic Repeat) technology by geneticists at the Medical University of South 
Carolina. They were able to successfully knock-in the exact DZIP1 mutation that was also 
exhibited in our MVP patients (Figure 2.5) and through histological applications it was 
determined that our Dzip1S14R/+ knock-in mice revealed MVP phenotypes as well like 
myxomatous degeneration (Figure 2.6). In order to gain more insight on how mutations in 
DZIP1 cause MVP, a two-hybrid screening was performed. In the results of the two-hybrid 
screening we found a pre-mRNA processing protein, called Prpf8, to interact with our wild 
type DZIP1 plasmid component and not our mutant DZIP1 component. Prpf8 is considered 
the heart of the spliceosome as it is a main factor in regulating mRNA splicing (Grainger 
& Beggs, 2005). Protein expression of both Prpf8 and Dzip1 were also measured in adult 
tail fibroblasts taken from mouse models: wild type (Dzip1+/+) and mutant (Dzip1S14R/+ and 
Dzip1S14R/S14R), where we saw a decrease in expression in the mutant protein compared to 
wild type (Figure 2.7). This is the first indicator that there is a difference in gene expression 
possibly due to the point mutation in Dzip1.Therefore, we concluded that our data from 
familial and genome wide association studies have indicated that DZIP1 and an interacting 







Figure 2.4 Dzip1 is Expressed at the Base of Primary Cilia in the Murine Mitral 
Valve. (A) Section of the mitral valve in situ at E14.5 shows robust Dzip1 mRNA 
expression in the anterior and posterior mitral leaflets (AL, PL, respectively). (B) IHC for 
Dzip1 (red) and axonemes (green) or basal bodies (green) showing expression of Dzip1 
at the basal body in E10.5 AV cushion mesenchyme. (C) Max projection image 
from high-resolution confocal microscopy of an E13.5 AV 
cushion mesenchymal cell showing Dzip1 (red) localized to the base of the ciliary 
axoneme (arrowhead) and the nucleus (arrows). (D) 3D reconstruction of the image in 




Figure 2.5 Developmental Basis for Non-syndromic MVP. (A-C) Movats Pentachrome staining 
shows valve enlargement, elongation, and myxomatous degeneration in the Dzip1S14R/+ mitral 
anterior and posterior leaflets (Al, PL) compared to control (Dzip1+/+). n=4/genotype. (D) 
Echocardiography of adult (6-month-old) Dzip1S14R/+ mice shows thickened and elongated anterior 
and posterior leaflets (AL, PL) that prolapse into the left atrium. n=4/genotype. (E, F) 3D 
reconstructions show bulging and excess tissue in the anterior leaflet (arrowheads) and an elongated 
posterior leaflet in Dzip1S14R/+mice compare to controls    (Dzip1+/+). (G-I) IHC shows shortened 
and loss of axonemes (green) in the Dzip1S14R/+ mitral leaflets, **p<.01. Red-basal bodies (gamma 




Figure 2.6 Dzip1S14R/+ Point Mutation Results in a Congenital Dysmorphic Mitral Valve 
Phenotype. (A) H&E staining of mitral valves from control (Dzip1+/+) and Dzip1 point mutation 
knock-in (Dzip1S14R/+) mice shows dysmorphic anterior and posterior leaflets at P0. Arrowheads 
point to valve leaflets of irregular shape in the knock-in model (Dzip1S14R/+) compared to controls 
(Dzip1+/+). (B) Quantification of valve 3D reconstructions of wild type and Dzip1S14R/+ point 
mutation mitral leaflets.  n=5 animals/genotype analyzed, and error bars represent standard error 
of mean. * p-value <0.05. AL, PL=anterior and posterior leaflets, respectively (Image by Diana 















Figure 2.7 Protein Expression of Prpf8 and Dzip1 in Adult Tail Fibroblasts. Adult 
tail fibroblasts were isolated from Dzip1+/+, Dzip1S14R/+ and Dzip1S14R/S14R animal models 
and had less Dzip1 protein expression than the control. Protein expression of Dzip1S14R/+ 
and Dzip1S14R/S14R quantified at molecular weights: 105 kDa and 99 kDa had a significant 
decrease (noted *= p value is <0.05 and **= p-value is <0.0005) in Dzip1 protein 






Two- Hybrid Screening 
The Two- Hybrid Screening was designed to establish direct protein-protein 
interactions by a simple bait-prey concept that examined the physical interactions of the 
protein(s) in question. The basis behind this technology can uncover various proteins as 
well as DNA interactions that can lead to a network of integrated components. In the 
relation to our studies with MVP and our discovery of DZIP1, a yeast two-hybrid (Y2H) 
was performed to discover the binding partners of Dzip1. Traditionally, the Y2H, looks at 
protein interactions through reporter genes that are activated once one is detected in the 
bait and prey system. These reporter genes enable a distinct color reaction and the cDNA-
library screen searches for pairwise interactions between defined proteins of interest 
(bait) and their interaction partners (preys) present in cDNA libraries or sub-pools of 
libraries. Here, preys are not separated on an array but pooled and libraries may contain 
cDNA fragments in addition to full length ORFs, thus largely covering a transcriptome 
and reducing the rate of false negatives (Bruckner, Polge, Lentze, Auerbach, & 
Schlattner, 2009).  
Given this technique, we decided to look at both wild type DZIP1 plasmid and 
mutant DZIP1 plasmid to see what interactions we could discover. Through this study we 
found numerous proteins that interacted with the wild type DIZP1 but uniquely enough 
there was only one protein that did not interact with our mutant DZIP1 plasmid, Prpf8. 
Being that Prpf8 was our only protein found to not interact with the mutant DZIP1 
plasmid, we hypothesized that:  
The Dzip1 regulation of ciliogenesis through a Prpf8 mRNA splicing mechanism is 
broadly involved in MVP disease. 
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At the heart of the spliceosome 
Prpf8 is classified as a splicing factor and mutations associated with Prpf8 result 
in a disease called retinitis pigmentosa. The design behind the pre-mRNA splicing 
mechanism is extremely intricate, as each step is important in forming a mature mRNA 
strand, which is through the spliceosome which removes introns. Pre-mRNA splicing is 
made up of two trans-esterfication reactions within the spliceosome complex. Prpf8 is the 
central component of the spliceosome and is considered the essential factor of this unique 
complex (Figure 2.8). The components of the spliceosome are made up of small nuclear 
RNA-protein complexes: U1, U2, U4, U5 and U6. Prpf8 is a component of the U5 and 
the tri-snRNP formed with U5+U4/U6. The snRNPs are encountered by various RNA-
dependent NTPases/RNA unwindases that catalyze each trans-esterification reaction, 
progressing the spliceosome to perform its job. Although, Prpf8 has been established as a 
splicing factor, its classification took a series of experiments to confirm.  
In 1967, Lee Hartwell and coworkers performed a genetic screen to isolate 
temperature-sensitive (ts) mutations in Saccharomyces cerevisiae (Hartwell, McLaughlin, 
& Warner, 1970). They identified 10 complementation groups, rna2-rna11, of mutations 
that caused accumulation of RNA following a shift from the permissive (23°C) to the 
restrictive (36°C) temperature. Many of these RNA genes were later renamed PRP genes, 
to indicate their involvement with pre-mRNA processing (Vijayraghavan, Company, & 
Abelson, 1989). These results identified the RNA8/PRP8 gene product as an essential 
mRNA splicing factor that was involved early in the splicing process. 
Finally, the discovery of Prpf8 was crucial in fully understanding the pre-mRNA splicing 
process, making it primarily seen within the nucleus on heart tissue once stained. A 
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previous study focused on Prpf8 and its association with primary cilia and found the 
Prpf8 localized to the base of the basal body. This insight was very informational as we 




















Figure 2.8 The Cycle of the Spliceosome. Schematic diagram showing the assembly and 
recycling of spliceosome components, with respect to Prpf8. Prpf8 has been found in two 
different U5 complexes: the U5 snRNP (small, yellow) and the larger U5/Prp19 snRNP 








Protein Expression of Dzip1 and Prpf8 
The expression of Dzip1 was analyzed through immunohistochemistry stains, co-
staining with cilia biomarkers. Dzip1 can be seen co-localized to the base of the ciliary 
axoneme, throughout valve development. (Figure 2.9). This coincides with the role of 
Dzip1 as it is required for ciliogenesis. Being that Prpf8 is a splicing factor, its expression 
is primarily within the nucleus, seen on immunohistochemical stains. Although, a 
previous study has also found that Prpf8 is expressed at the base of the basal body of 
primary cilia. 
Preliminary data was also performed by western blot analysis to confirm that 
there is more of presence of Dzip1 and Prpf8 in wild type compared to mutant mouse 
model. This was evaluated by collecting protein from mouse models (Dzip1+/+ and 
Dzip1S14R/+) and probing for Dzip1 and Prpf8 with their respective antibodies (Figure 
1.7). By analyzing the results of the Two-Hybrid Screening, we were able to start the 
journey of uncovering the connection between the two proteins, Dzip1 and Prpf8. Our 
first step was to confirm that both, Prpf8 and Dzip1 were co-expressed and co-localized 
together on the mitral valves. To verify this further immunohistochemical stains were 
performed co-staining for both proteins on Dzip1+/+ heart tissue. Stains show that the 
proteins are in fact co-expressed and co-localized with one another on the mitral valves.  
Validation of Two-Hybrid Screening  
Given the information provided from the Two-Hybrid Screening we looked to 
reproduce those results. Therefore, we performed a co-immunoprecipitation, where we 
collected protein from adult tail fibroblasts from our wild type and diseased knock-in 
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mouse model. We simply immunoprecipitated the protein with Prpf8 IgG and probed for 
Dzip1. 
Through this application we were able to directly verify that the Dzip1 mutation impairs 























Figure 2.9 Prpf8 and Dzip1 Expression on the Valve. (A) Immunohistochemistry on 
wild type mouse heart tissue shows Dzip1 (red), Prpf8 (green) and nuclei (blue) being 
expressed on the posterior leaflet at postnatal age P0. (Bottom panel) is a 3D 
reconstruction image completed with Imaris software to show at a greater magnification 







Figure 2.10 Dzip1 Mutation Alters Prpf8 Interaction. Co-IP showing that the 
Dzip1S14R mutation impairs interactions with the PRPF8 splicing factor. Endogenous 
proteins were immunoprecipitated with Prpf8 IgG and probed with Dzip1. Prpf8 binding 
is greatly reduced (asterisk) in the mutant. Prpf8 was probed on the same blot to ensure 
comparable amounts of protein was immunoprecipitated. Input lanes showing total Dzip1 










Although the genetics behind MVP are still developing, the beginning stages of 
fully understanding which genes cause this disease are examined through these various 
studies. The mechanism by which Dzip1S14R/+ causes MVP is still not understood but as 
we take a closer look at Dzip1 and Prpf8 we begin to form a broad hypothesis that the 
mechanism by which Dzip1 mutations result in MVP is directly related to mRNA 
splicing, via splicing factor Prpf8.   
These studies illustrate the interaction between Dzip1 and Prpf8 is present as is a loss of 
protein expression in mutant mouse model. The mutation impairs interaction between 
Prpf8 and Dzip1 and this gives us a broad idea of how the two are interacting and that the 
mutation is significantly affecting that interaction.  
Further experiments are needed to firmly understand at which point in time the two 
protein interact and by which mutations in Dzip1 cause a disruption of Prpf8 not 
performing its main role properly.  
In order to further investigate this, plausible pathways in which the two are 
interacting needs to be determined. For instance, known signaling pathways in relation to 
primary cilia are: Hh, Wnt, Notch, and TGFb to name a few. In addition, truncation 













































There has been much debate on whether primary cilia play a role in early age 
development. Before there was any evidence on these organelles, many believed that they 
simply held no significant function.  However, through several studies we know this 
notion to be false. We have learned that not only are primary cilia expressed on the mitral 
valves (heart) during early development but they are expressed on the kidney, retinal, and 
neurological cells. There has been genetic evidence that have directly associated 
mutations in cilia to a plethora of diseases that afflict the liver, heart and brain. This is an 
example of a ciliopathy, which is when a genetic mutation encoding defective proteins 
results in the abnormal function or formation of primary cilia (Beales et al., 2007). The 
term ciliopathy was first coined when Ansley et. al discovered genetic mutations in 
BBS8, which resulted in the phenotype of Bardet-Biedl syndrome (BSS) (Ansley et al., 
2003). This finding paved the way for further investigations on how organelles that were 
thought to be nonsignificant affect normal function in development.  
To date, approximately 1,000 polypeptides have been linked within the ciliary 
proteome (Gherman, Davis, & Katsanis, 2006). Specifically, mutations in IFT80, encodes 
an intraflagellar transport protein in a subset of patients with Jeune asphyxiating thoracic 
dystrophy (JATD). It has been found that patients with JATD exhibited typical ciliopathy 
features like retinal degeneration, renal disease and skeletal dysplasia (Beales et al., 
2007). This has led to many studies that centered around exploring the signaling 
mechanisms and the proteins involved in the building of primary cilia, which is known as 
ciliogenesis. Many researchers have explored the pathways of Wnt and Hedgehog 
signaling as well as the proteins involved in these pathways. Specifically, it has been 
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found that through several genetic screens that there is a connection between mammalian 
Hh signaling and intraflagellar transport (IFT).  For example, Ift88, Gli family members 
and Smoothened (Smo). Recent studies within our lab have identified the direct 
association with Hh signaling and primary cilia during mitral valve development.  
Results  
Hedgehog Signaling  
Hedgehog Signaling has become one of the most well-studied signaling pathways that 
has been directly associated to primary cilia. This pathway has been essential for 
development in many organs. Evidence has shown that many components involved in 
Hedgehog signaling have co-localized to base of primary cilia (Figure 3.1). In this 
pathway there are receptors, Patched (Ptch1) and Smo that travel up and down the 
axoneme of the cilia. They do this as a response to the hedgehog ligands: sonic (Shh), 
Indian (Ihh) and desert (Dhh). Patched is considered a negative regulator of this pathway 
because in the absence of ligand Ptch1 inhibits the activation of Smo. While, in the 
presence of Hh ligand Ptch1 removes the inhibition of Smo and allowing it to move up 
the ciliary axoneme. As Smo enters the ciliary axoneme it interacts with Sufu, which in 
turn allows the processing of Gli family members: Gli1, Gli2 and Gli3). In regard to Gli 
transcription factors they can be either activators or repressors. If there is absence of Hh 
ligand then the Gli transcription factors are restricted to their repressor forms. As we 
begin to look at other components involved in ciliogenesis, we discover the important 
role that IFT proteins play in Hh signaling. Knowing this our lab examined the loss of 
Ift88, which is a centrosomal protein required for ciliogenesis. Compared to the wild type 
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there is an increase in the enlargement of the ECM (Figure 3.2) in our Ift88f/f NfatC Cre+ 
mouse model. 
As mentioned earlier Gli transcription factors can either be in a repressed (GliR) 
or active state (GliA). IFT proteins are required for the production of GliA and GliR and 
consequently the disruption of these proteins disrupts Hh signaling (Haycraft et al., 
2007). Each transcription factor of Gli plays an important role in development as they are 
directly involved in Hh signaling. To summarize the activation of Gli1 activates that Hh 
pathway through Gli2 and Gli3 activation. Gli2 is responsible for regulating fibrotic 
signals and Gli3 is essential for basal suppression of the Hh pathway. All of which 
directly and indirectly affect the progression of ECM genes downstream in Hh. This 



















Figure 3.1 Hedgehog Signaling through Primary Cilia.  Hedgehog signaling at the primary 
cilium in vertebrates. (A) In the unstimulated state, Ptc1 sits in the cilium membrane and 
represses and excludes Smoothened (Smo) from the cilium. Gli transcription factors are 
sequestered and suppressed by Suppressor of Fused (SuFu) at the tip of the primary cilium. (B) In 
the stimulated state, upon binding of Shh to Ptc1, the repression of Smo by Ptc1 is relieved, 
allowing Smo to enter the cilium and Ptc1 to leave the cilium. This then allows Smo to repress 
SuFu, relieving repression of Gli at the tip of the cilium. Gli is thus freed to be post-
translationally modified to form Gli activator form (GliA), which is transported out of the cilium 
to the nucleus to activate expression of downstream target genes (Wheway, Nazlamova, & 






Figure 3.2 Loss of Ift88 Results in Myxomatous Degeneration. (A) H&E staining and 
3D reconstructions show that loss of Ift88 results in valve enlargement in both anterior and 
posterior leaflets (black arrowheads). (B) Quantification of valve 3D reconstructions of control 
(NfatC1Cre(+);Ift88+/+) and Ift88 conditional knockout (NfatC1Cre(+);Ift88f/f) mitral leaflets. *p-




Differences in Gene Expression 
A cell’s function is dependent on its complex transcriptional material. Many 
researchers have turned to RNASeq, a technique that provides fundamental information 
from within the cell.  Furthermore, this application can examine the expression levels of 
genes and deliver knowledge on genes that have yet to be discovered.  It has also been 
demonstrated that splicing variants  and single nucleotide polymorphisms (Sultana & 
Wang, 2008). can be detected through sequencing the transcriptome, opening up the 
opportunity to interrogate allele-specific expression and RNA editing. Knowing the 
impact that IFT proteins have on the building of primary cilia, we designed mouse 
models: NfatC1Cre(+); Ift88f/f and NfatC1Cre(-), Ift88+/+ (Figure 3.3). In our NfatC1Cre(+); 
Ift88f/f  model we see almost a complete ablation of primary cilia, where any remaining 
cilia is severely shortened compared to our NfatC1Cre(-), Ift88+/+. Therefore, to study the 
differences in gene expression we conducted a RNASeq analysis where we dissected 
mitral valve leaflets from our Dzip1 knockin and wild type mouse models and isolated 
RNA (Figure 3.4). 
This study paved the way for us to perform the same study on our knockin mouse 
models, Dzip1S14R/+ and Dzip1+/+. Through examining these two models we found a 
significant difference in gene expression in subsequently the protein Ift88. As stated 
earlier Ift88 is a centrosomal protein and is required for ciliogenesis. This discovery made 
Ift88 a plausible ciliary target for Prpf8 as we believe that this splicing factor would not 
be able to fulfill its job correctly in the presence of the Dzip1 mutation. Overall, the 
differences in gene expression was the first indicator that there is possibly another factor 




Figure 3.3 Loss of Cilia in Ift88f/f Nfatc1 Mice. IHC showing loss of cilia expression in 
conditional knockout animals. Axonemes in green and basal bodies in red. Arrows 
pointing to cilia expression; arrow heads pointing to loss or shortened cilia (Image by 





Figure 3.4 RNAseq Analyses Correlate Loss of Cilia with ECM Gene 
Activation. (A) Heat map of RNAseq data from the anterior leaflets of Ift88 conditional 
knockout (NfatC1Cre(+);Ift88f/f) and control (NfatC1Cre(+);Ift88+/+) P0 mitral valves 
showed large increases in the expression of extra cellular matrix gene transcripts. (B) GO 
analyses of an additional RNAseq dataset also revealed an upregulation of ECM gene 
pathways in Dzip1S14R/+ hearts compared to controls at E13.5, supporting the previous 









RNASeq intricately evaluates gene expression within the cell. Yet, DEXSeq 
tackles the regulation of these processes requires sensitive and specific detection of 
differential isoform abundance in comparisons between conditions, cell types, or tissues. 
Therefore, we use DEXSeq to test for differential exon usage from the RNASeq data 
obtained previously.  Specifically, the DEXSeq uses generalized linear models and offers 
reliable control of false discoveries by taking biological variation into account. This 
method also enables the study of regulation and function of alternative exon usage on a 
genome-wide scale. (Anders et.al 2012). Transcript count data from the analysis of the 
samples were sorted according to their adjusted p-value or q-value, which is the smallest 
false discovery rate (FDR) at which a transcript is called significant. Resulting in a list of 
significant genes that were alternatively spliced between the mouse models: Dzip1S14R/+ 
and Dzip1+/+. Furthering the investigation behind uncovering the possible role splicing 
played between the two models. In order to ensure that the results we received had a basis 
we completed a series of western blots to examine a difference in splicing in these 
significant proteins. Ultimately, this would give us knowledge on which proteins are 







Table 3.1 Alternative Splicing Detected. The list of genes that had differential exon 
usage in Dzip1+/+ compared to Dzip1S14R/+ mouse valve leaflets. The exon (s) that 











Table 3.1 Genes with alternative splicing in mutant Dzip1 valve leaflets compared to wild type 
Dzip1. 
Gene Name Exon Number p-value 
Rab11a E1 9.02e-08 
Sept7 E36 1.58e-07 
Tuba1a E2 7.45e-07 
Tubgcp3 E2 0.00030098 
Smo E14 0.00045523 
Glis2 E7 0.00067927 
Ift88 E19-24 <1X10e-09 
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Ciliary Targets Revealed  
The DEXSeq was the next step in pinpointing the differences in splicing in the 
presence of the mutation found in Dzip1S14R/+. As it has been previously mentioned Prpf8 
is a central component of the spliceosome, making its role critical in pre-mRNA splicing. 
Knowing this knowledge, we closely examined the genes that were being alternatively 
spliced. A few of the genes found had been implicated in the process of ciliogenesis, for 
example, Ift88 and Smo, because of this factor it fueled the notion that in the presence of 
the point mutation Prpf8 is unable to perform its job correctly, subsequently disrupting 
the formation of primary cilia. To investigate this further a western Blot analysis was 
used to identify alternative splicing. Protein was collected from mouse embryonic 
fibroblasts, both wild type and mutant to evaluate a change in expression.  
Furthermore, this expression was seen in the following targets, probed with their 
respective antibodies: Tubgcp3 (Tubulin Gamma Complex Associated Protein 3), Ift88, 
and Glis2 (GLI Zinc Finger Protein 2). While these are only a few of the proteins 
identified in the DEXSeq, these proteins showed a significant change, quantified through 
western blot analysis (Figure 3.5). Although there was no significant data obtained 
through western blot analysis that supports Smo being alternatively spliced, other genes 
like Tubgcp3 and Glis2 prove otherwise. All of these genes have been previously 
associated with the building of primary cilia. For instance, TUBGCP3 job consists mainly 
of gamma-tubulin binding. Tubgcp3 is a cilia- associated protein and mutations of 
TUBGCP3 can lead to cardiomyopathy, Dilated, 1P (Spudich, 2014) (Lu et al., 2015). 
Recent studies show that the loss of GLIS2 leads to diseases like progressive kidney 
atrophy, interstitial inflammatory infiltration, and fibrosis (Attanasio et al., 2007). Oddly 
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enough all the proteins encoded by the genes mutated in cystic kidney diseases are 
localized to the primary cilium of kidney epithelial cells, this includes Glis2. Finally, 
Glis2 is a paralog of another Hh inhibitor, Gli3, whose activity is dependent on primary 
cilia (Masetti et al., 2017). 
Discussion  
Through the DEXSeq we were able to confirm that there are in fact proteins that 
are being affected in the mutant mouse model that otherwise would not be in the wild 
type. All of these proteins have been associated with the production of primary cilia in 
some way. This supports evidence that Prpf8’s inability to interact with Dzip1 is 
detrimental for ciliogenesis. This further indicates that Prpf8 is not functioning as it 
would under normal regulations. These proteins that are being alternatively spliced give 
us an understanding on what the key players are on our proposed Dzip1 mechanism. 
Although the western blot application does not definitively confirm alternative splicing in 
the probed ciliary targets. It certainly suggests this is a possibility. In future experiments 
alternative splicing can be confirmed by reverse transcriptase polymerase chain reaction 
(RT-PCR) and can be used to also determine a plausible connection involving all moving 










Figure 3.5 Ciliary Targets Have a Difference in Isoforms in Dzip1+/+ Compared to 
Dzip1S14R/+ in Mouse Embryonic Fibroblasts. (A) Western Blot Analysis was 
performed on protein taken from Dzip1+/+ and Dzip1S14R/+ mouse embryonic fibroblasts 
(MEFs). “1” = wild type Dzip1 MEFs and “2” = Dzip1S14R/+ MEFs. Dzip1 blots were 
probed with respective antibodies Glis2, Ift88 and Tubgcp3 (1:1000) n= 3. (B) 
Quantification of Ift88 shows significance in band intensity in Dzip1+/+ and Dzip1S14R/+ 
























































Non-syndromic MVP affects between 2-3% of the world’s population and there 
have been recent studies that question the genetic heterogeneity of MVP. The current 
findings of linked loci to the (Disse et al., 1999) disease and previous family studies that 
indicate rare connective tissue syndromes (Holbrook & Byers, 1989) verify that MVP is a 
disease that can be characterized by the mutations of multiple genes. Thus far in the 
project we have focused our studies on the large family with non-syndromic MVP, which 
gives us a high-effect because of how rare the point mutation is in the general population. 
Yet we have neglected to see whether or not there is a link between MVP, DZIP1 and 
PRPF8 given a larger sample size (lower effect size). Therefore, we reexamined many of 
the findings from an MVP GWAS conducted on the general population. First, a GWAS 
Meta-analysis (Table 4.1) was conducted including 1,412 MVP cases and 2,439 controls. 
Through this study there were 6 significant loci found.  
As previously mentioned, genes TNS1 and LMCD1 were the first two significant 
loci and both came with supported scientific evidence that showed knockdown of 
LMCD1 led to mitral regurgitation and Tns1-/- mice showed myxomatous degeneration in 
the posterior leaflet. The third most significant locus was SMG6 and to date there had 
been no known significant data that ties an MVP phenotype to SMG6. Additionally, 
scientists have discovered that knockdowns of SMG6 in zebrafish exhibit no valvular 
phenotype (Dina, et. al 2015). By further examination it was discovered that SMG6 
resides on chromosome 17. This information was particularly interesting because PRPF8 
is located on chromosome 17 as well. Furthermore, the MVP SNP is positioned in the 
SMG6 intron and it is in close proximity to the PRPF8’s gene locus, approximately 
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500bp (Figure 4.1). This led us to hypothesis that this MVP SNP could be acting as an 
enhancer for Prpf8. 
In a normal reaction that involves the expression of a gene, there is an enhancer 
and the enhancer’s responsibility is to properly interact with the promoter site 
(specifically the transcription start site) and effectively turn the gene “on”. However, the 
enhancer will not be able to perform its job correctly if there is a mutation inhibiting its 
correct function. Therefore, the interaction is lost, and the gene will be “off”, stopping 
any regulation of the gene. Furthermore, we completed a luciferase assay to test whether 
the putative enhancer had any capabilities for enhancer activity. In addition, our 
collaborators at INSERM completed a 3C experiment, where they were able to isolate 













Table 4.1 Clinical and Genotyping Features of the Study Populations. The table 
illustrates the study design behind the GWAS. The study design with cohorts in discovery 



















Figure 4.1 Genomic Context of the Association Signal Observed in MVP GWAS 
Meta-Analysis on Chr17p13.  Prpf8 is circled in red. SMG6 is located below thhe 
position of the MVP SNP is denoted as rs216205 (purple dot) (Image by Nabila Bouatia-









Results   
“Silencer” Identified  
Primers were designed to include the correct wild type sequence of the genetic 
variant found on chromosome 17 (Table 4.2). Once this was found we amplified the 
sequence and performed a ligation to fuse both the insert and the pre-cut PGL2- promoter 
vector. The vector backbone contained a luc gene, which would be expressed if there was 
any enhancer activity detected in the insert (MVP SNP- wildtype). Next, we performed a 
transformation and sequenced the positive colonies to ensure that we had the accurate 
sequence. Transfections were followed on chicken valvular interstitial cells (cVICs) and 
human embryonic kidney cells (HEK293T), where they were completed in triplicates and 
repeated three times. The luciferase assay was performed 48 hours after transfection to 
measure for enhancer activity.  
The results significantly showed that the putative enhancer was in fact showing 
activity that resembles a repressor (Figure 4.2). This indicates that in normal conditions 
the wild type variant is a “silencer”. There are future experiments that need to be 
completed to show the activity of the MVP SNP once cloned into the PGL2-promoter 
vector, this would give us better understanding on how the enhancer could be affecting 
PRPF8 regulation. Additionally, each insert (MVP SNP and MVP SNP wildtype) need to 
be cloned into a PRPF8 vector and measure its level of enhancer capabilities under more 
relevant conditions. Therefore, we would be able to determine each insert’s 
characteristics and conclude whether or not they align to the results found in the PGL2-
























Figure 4.2 Silencer Identified. HH31 chicken valvular interstitial cells (10X105 cell 
count) were transfected with the PGL2 promoter reporter and insert constructs labeled 
sense orientation and antisense orientation, pGFP and PGL2 promoter vector alone for a 
control. Each plate was treated with bGal to normalize the rate of transfection.  After 72 
hours, plates were examined and assayed using the Promega Luciferase Assay Kit. (A-C) 
Each graph shows triplicate series performed. (D) Compiled data from three series of assay 




Potential Regulatory Sequences  
In order to take the task on to finding the enhancer that directly interacts with the 
TSS for PRPF8. Our collaborators in INSERM performed a Chromosome Conformation 
Capture (3C) experiment. This pioneering technique is able to analyze significantly long 
range looping interactions between any pair of selected genomic loci (Naumova, et. al 
2012). This experiment tested physical interactions between genomic sequence 
containing the most associated SNP with MVP at Chr17 (rs216205), and several genomic 
points at variable distance from the SNP that interact with the TSS of PRPF8. This was 
performed in two separate libraries: dermal fibroblasts and heart fibroblasts. While 
analyzing the result from the 3C experiment it is determined that there are three 
regulatory sequences that are in direct contact with the TSS of PRPF8 (Figure 4.3). 
 In contrast to linear genomic DNA, close points were amplified but not distant 
points. The presence of an amplified sequence on lane 6 indicates the TSS region of 
PRPF8. Lanes 1, 2 and 3 tested positive for interacting with the TSS region of PRPF8 
(Figure 4.4). A fourth sequence was found based off of information obtained from a 
computer data basis that showed that it is a possible enhancer for PRPF8 (Figure 4.3). 
Additionally, sequences 1-3 were all short distances from the found MVP SNP 
(rs216205). Sequence 1 is 75kb away from the MVP SNP followed by sequence 2 which 
is 93kb from the MVP SNP and finally sequence 3 is 116kb from the MVP SNP. Given 
the original size of each sequence found an Assay for Transpose-Accessible Chromatin 
with high-throughput sequencing (ATAC-seq) was performed to ultimately condense the 
size of each sequence to approximately 200bp by performing amplifying the open 
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chromatin with the use of the enzyme transposase (Shrestha, Ding, Jones, & MacLean, 
2018).  
Primers were designed for all four sequences (Table 4.3) and they were cloned into the 
PGL2-promoter vector and examined for enhancer function, through ligation and 
transformation steps (Figure 4.5).   
The sequences were transfected into HEK293T cells, due to the fact that 
HEK293T cells can be easily transfected and they are a part of the human genome, 
making all sequences cloned 100% conserved.  A luciferase assay was conducted to 
measure enhancer activity. The measurements and quantifications are listed (Figure 4.6). 
Through this application we were able to decipher which sequences had enhancer 
capabilities. We were fortunate enough to clone in the mutation for the 1st regulatory 
sequence and apply this to our theory. This resulted in confirming that the 1st regulatory 
sequence had significant enhancer capabilities compared to the PGL2 promoter vector. 
The remaining sequences (2,3 and 4) were ruled out as they did not exhibit any 
significant enhancer activity. This finding gives us insight on how PRPF8 is being 
regulated in the presence of the Dzip1 point mutation. Furthermore, in addition to the 
previous “silencer” found and both versions of sequence 1 (mutation and wild type) need 
to be cloned into a PRPF8 vector backbone to test for enhancer activities in the presence 
of the PRPF8 TSS and determine whether each sequence of 1 and the repressor carry the 
same behavior seen in the PGL2 promoter vector.  
Discussion 
Each sequence tested gave us a closer look into the various possible reasons as to 
how the regulation of Prpf8 is being affected in the presence of the Dzip1S14R/+ mutation. 
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The significant findings of the repressor in the wild type version of our MVP SNP 
indicated that there may be a series of events unfolding that are untraditional in the sense 
that in normal settings there is a detected “silencer” in close proximity to the TSS of 
PRPF8. As stated earlier, further studies need to be completed that show a definitive 
significant change in either of the sequences compared to the lone PGL2-promoter 
vector. Furthermore, we were able to verify enhancer capabilities by cloning each 
sequence into the PGL2 promoter vector. Yet, in order to understand the nature of 
PRPF8’s regulation the enhancer needs to be cloned with a PRPF8 backbone. Our 
previous studies are promising as it laid the groundwork for future experiments and 















Table 4.2 SNP Region Cloned. Primer sequences used for Cloning/Sanger Sequencing 
MVP SNP (rs216205) region. 
Primers used to isolate MVP SNP region 
               Primer Name                Forward Primer               Reverse Primer 

























Table 4.3 Potential Regulatory Sequences. Primers for potential regulatory sequences 
found through 3C experiment.  
                               Potential Regulatory Sequences 
                Sequence              Forward Primer              Reverse Primer 
Regulatory Sequence 1 5’-CTA AAT TCT GCA 
GTG ACA CA-3’ 
 
5’-AAT GAT GCA ATG 
AGC CAA AC-3’ 
 
Regulatory Sequence 2 5’-TGC CCT GGG AAG 
ACC GTG GA-3’ 
 
5’-GAG CCA CCA CAC 
CAG GCC AT-3’ 
 
Regulatory Sequence 3 5’-CTA CAA TCC GGC 
TTC CAG TT-3’ 
 
5’-TGA TAC AGG TGG 
TGG TTG AA-3’ 
 
Regulatory Sequence 4 5’-AGA GAA AGA ACT 
ATT TGA AG-3’ 
 
5’-TTC GAA ACT GCA 

























Position of rs9899330 is in Red. Noted as Regulatory Sequence 1 
 
 





Position of rs749240 is in Blue. Noted as Regulatory Sequence 2 
 
 





Position of rs17834627 is in Green. Noted as Regulatory Sequence 3 
 
 









Figure 4.3 Potential Regulatory Sequences. 3C experiment was completed to determine 
the sequences with physical interaction to the MVP SNP (rs216205) region and the TSS 




























Figure 4.4 Chromatin Conformation Capture of PRPF8 TSS and Potential Enhancers. 3C 
experiments on Chr17 MVP locus. (A) Chromatin conformation capture from two separate 
libraries (dermal and heart fibroblasts) tested physical interactions between genomic sequence 
containing the most associated SNP with MVP at Chr17 (rs216205), and several genomic points 
at variable distance from the SNP. In contrast to linear genomic DNA (B), close points were 
amplified (lanes 1, 2, positive controls) but not distant points (lanes 4 and 5, negative controls). 
The presence of an amplified sequence on lane 6 indicates that despite the linear distance between 
the 2 points (600Kb), the SNP and the TSS region of PRPF8 are close in the native chromatin that 
we captured through the 3C experiment.  (C) Chr 17 locus with segments (1-6) that were tested in 
3C libraries.  PRPF8 transcription start site (tss) is denoted in yellow (Image by Nabila Bouatia-






Figure 4.5 Luciferase Assay Measures Enhancer Capabilities in Potential 
Regulatory Sequences.  All potential sequences were cloned and tested for RLU levels 
in comparison to PGL2 vector. 1st Regulatory Sequence (mutation) A had significant fold 
change and RLU levels. Antisense of 1st sequence was cloned to compare the mutation in 























































Mitral valve prolapse is one of the most common cardiac diseases, affecting on average 3 
million people nationwide. The function of prolapsed valves results in regurgitation, 
arrhythmias and even sudden cardiac death in severe cases. The phenotype of these 
valves includes myxomatous degeneration, resulting in an increase in proteoglycans, 
fragmented collagen and hyperplasia. 
Currently invasive surgery is the only option to replace or repair the valves. While the 
etiology of this disease is still not fully understood, studies within our lab suggest that 
primary cilia play a critical role in the valve disease.  
Primary cilia have been found to play a central part in valvular development as mutations 
that disrupt the formation of primary cilia lead to improper valve development. This is 
due to the role that cilia have been proven to regulate cell cycle, proliferation and matrix 
deposition. Studies show that signaling through them regulates ECM production, while 
current studies are providing more insight on hedgehog signaling being the main pathway 
for this.  
Primary cilia are temporally expressed on the leaflets of the mitral valve and are 
noticeably absent at adult timepoints. This indicates that they are essential for early stage 
development. This begs the question, why do we see this diagnosis of MVP in adults 
rather than when cilia are actually present on the valve? 
Overall, as the patients ages, the enlarged postnatal leaflets cause the endothelial borders 
to stretch, causing breaks that allow for a cytokine release and infiltration of extracardiac 
cells, furthering the enlargement of the valves and thus causing valves to lose normal 
function.  
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Over the past few years scientists have strived to investigate the mechanisms by which 
primary cilia contributes to valve disease. Our hypothesis proposed at the beginning of 
this project was that the Dzip1 regulation of ciliogenesis through a Prpf8 mRNA splicing 
mechanism is broadly involved in MVP disease. The studies previously outlined looked 
to test whether adequate data could be collected to support this.  
By establishing that both Prpf8 and Dzip1 were co-localized and co-expressed together 
on the mitral valve serves as a foundation to the previous studies. This evidence supports 
the findings from the two-hybrid screening and from the data collected we propose the 
following working model.  
As it has been stated primary cilia serve as mechanosensors for the cell and signaling 
through them has been shown to regulate cell cycle, proliferation, and migration. Recent 
studies within our lab show that defects in primary cilia have a higher prevalence for 
MVP. This association has led to several genetic studies that link mutations in DZIP1 to 
many MVP patients. Dzip1 experiences many different interactions but one stood out in 
particular, Prpf8 as it was the only protein that was unable to bind to DZIP1’s mutant 
plasmid in a two-hybrid screening.  
Furthermore, the mutation in Dzip1 disrupts Prpf8’s job to splice mRNAs encoding 
proteins that affect the process of ciliogenesis, i.e. Ift88. Ift88, a centrosomal protein that 
is required for the building of cilia shows evidence of being alternatively spliced. Other 
ciliary proteins that have a difference in splicing isoforms are: Tubgcp3 and Glis2.  
By investigating the interaction of PRPF8 and DZIP1 we were determined to take a 
closer look at what could be enhancing the regulation of PRPF8. We examined many 
different potential enhancers. First we found that there was an MVP SNP in close 
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proximity to PRPF8’s locus that could be affecting the regulation of PRPF8. The wild 
type sequence of the MVP SNP was cloned first into the PGL2 promoter, and it exhibited 
‘silencer” activity. Second, additional potential regulatory sequences were identified 
through the 3C experiment which tested the location surrounding the MVP SNP and if 
there was any direct physical interaction between it and the TSS of PRPF8.  The work 
completed has the ability to directly influence therapies for MVP.  
Furthermore, as we look at the cycle of discovery between MVP, DZIP1 and PRPF8, we 
examine them from two different perspectives. The first from a large non-syndromic 
family with MVP exhibiting a significantly rare point mutation in DZIP1 not commonly 
seen in the general population. The second from a broader perspective that involves 
examining the general population as a whole to investigate whether there is a common 
link between MVP, DZIP1 and PRPF8 in a larger sample size with a low effect size 
(Figure 5.1).  
Future studies are needed to further find the direct mechanism by which mutations cause 
valve disease, but studies performed in the project have increased the understanding 
behind genetic alterations in MVP. Therapeutic aids are promising, such  as developing 
one to target the reduction of further degradation or to provide complete function of the 
spliceosome in the presence of a point mutation as it relates to this research could result 
in non-invasive treatment for patients with MVP. The data provided gives us an 
understanding of the cellular and molecular cause of MVP as it relates to primary cilia 
and the genetic information that supports this hypothesis. Finally, the research presented 
specifies a broad mechanism by which mutations in Dzip1, a centrosomal protein needed 
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Figure 5.1 The Cycle of Discovery. Schematic diagram of the two perspectives taken in 
















































All mouse experiments were performed under protocols previously approved by the 
Institutional Animal Care and Use Committee (IACUC) at the Medical University of 
South Carolina. Prior to cardiac resection, mice were euthanized in accordance with the 
Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, revised 
1996.) Comparisons between sexes were evaluated and no significant differences were 
observed. As such, data is comprised of pooled sexes for all experiments.  
 
Dzip1 knockin mice  
Dzip1 knockin mice were generated through CRISPR technology. 
Scientists were able to take the exact Dzip1 point mutation that we found in patients with 
MVP into a mouse model. Founder lines 731 and 736 were utilized in the studies listed 
throughout this project. Mating strategies were as follows. Founder lines: 731 and 736 are 
both male and are genotyped to be heterozygous for the point mutation. The lines were 
mated with female C57/B6 mice from JAX Laboratories. Mice resulting from these 
mating would be either wildtype or  heterozygous for the Dzip1S14R/+ point mutation, 
resulting in an F1 generation. F2 generations were outbred as well in the same manner 
with male heterozygous mice and female wildtypes. All mice were inbred. The knockin 
mutant allele was genotyped using forward primer: 5’-
CATCAGAGGCTCACGAGGAG-3’ and reverse primer 5’- 
GCGTGGACAGCATCTTCTTC-3’. Histology was performed on embryonic and adult 
wild type (Dzip1+/+), heterozygous (Dzip1S14R/+) and homozygous (Dzip1S14R/S14R) hearts 
on mixed background.  
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Dzip1 conditional mice 
Conditional knockout mice were generated by a targeted homologous recombination 
approach using a Dzip1 targeting construct (PG00125_Z_2_E04) purchased from the 
KOMP mouse repository. The conditional knockout would delete exons 8 and 9 (Dzip1-
202 transcript) and cause a reading frameshift and premature translational termination. 
The conditional mutant allele was genotyped using forward primer: 5’-
GCCAAAGTGGTTTGCCTGACA -3’ and reverse primer: 5’-
GCAGGTTAAACACTCATATAGC-3’.  
 
IFT88 conditional mice 
Ift88 conditional mice and genotyping were previously described (Haycraft, Zhang et al. 
2007). Histology was performed on embryonic and adult wild type (NfatC1Cre-;Ift88f/f) 
conditional heterozygous (NfatC1Cre-;Ift88f/+) and conditional knockout 
(NfatC1Cre+;Ift88f/f) hearts on mixed background. 
 
Histology, Immunohistochemistry/Immunofluorescence 
Embryonic and adult tissue were processed for immunohistochemistry/ 
immunofluorescence (IHC) from Dzip1 knock-in mouse models (wildtype, heterozygous 
and homozygous). IHC staining was performed on 5 um thick sections from embryonic 
stages: E11.5, E13.5, E15.5 and P0 mitral valves. For immunohistochemistry (IHC): 
Antigen retrieval was performed for 5 minute using antigen unmasking solution (Vector 
Laboratories, Burlingame, CA, USA, Cat#H-3300) by pressure cooker (Cuisinart, 
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Stamford, CT, USA). The following are the antibodies and their dilutions; Acetylated 
Tubulin (Sigma, Cat#T6793, 1:500), Gamma Tubulin (Abcam, Cambridge, MA, USA, 
Cat#ab11317, 1:1000), Dzip1 (Santa Cruz, Cat#SC: 515454, Medical University of South 
Carolina, 1:250), Prpf8 (Abcam, Cambridge, MA, USA, Cat#ab185547 1: 50). Primary 
antibody was detected using fluorescent secondary antibody, Goat anti-Mouse IgG Alexa 
fluro 488 (Cat#A-11029, 1:100), Goat anti-Rabbit Alexa fluor 488 (Cat#A-11034, 1:100) 
anti-Mouse Alexa fluor 568 (Cat#A-11004,1:100), anti-Rabbit Alexa fluor 568 ). Nuclei 
were counterstained with Hoechst (Life Technologies, Cat#H3569, 1:10,000) for 10 
minutes and slides were coverslipped with SlowFade mounting medium (Life 
Technologies, Cat#S36937). Fluorescence imaging was performed using Zeiss 
Axioimager M2 and Leica TCS SP5 AOBS Confocal Microscope System. 
 
Confocal Microscopy 
Images were acquired using the Leica TCS SP5 AOBS Confocal Microscope System 
(Leica Microsystems, INc., 410 Eagleview Boulevard, Suite 107, Exton, PA 19341). Z- 
stacks were set by finding the highest and lowest depth with visible fluorescence and 
using the system optimized setting to determine steps. Z- stacks were then compiled to 
form maximum projection images.  
 
3D reconstruction 
3D reconstructions of H and E images were performed to generate volumetric 
measurements of postnatal day 0 right, left, and non-coronary leaflets, similarly to 
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previous reports. Images were then aligned using ImageJ FIJI and imported into Imaris 
8.0. Manual reconstruction was performed by tracing each individual cusp on every 
section and combining all traces to create a 3D structure. Additionally, 3D 
reconstructions of immunohistochemistry were performed by importing Z-stack images 




Hek293T and cVICs cell lines were ordered from Thermo Fisher. Adult tail fibroblasts 
were generated from Dzip1 knockin tail snips (genotypes: wildtype, heterozygous and 
homozygous) at ages ranging between 2-4 months old. Hek293T, cVICs and adult tail 
fibroblasts were cultured in a 37 degree Celsius, 5% CO2  incubator, all in their respective 
media. Hek293T and Adult Tail Heks and fibroblasts cells were incubated in DMEM/ 
High Glucose media (Corning™ DMEM with L-Glutamine and 4.5g/L Glucose; without 
Sodium Pyruvate, cat#10-017 CV), with 10% fetal bovine serum (FBS) (XYCellCulture, 
cat #FBS-500, Kansas City, MO) and 1% Penicillin/Streptomycin mixture (Life 
Tecnologies, cat#15070-063 Carlsbad, CA ). cVICs were incubated in Medium 
199/EBSS media (Hyclone™+ Earle’s Balanced Salts+ L-Glutamine), with 10% chicken 
serum (Bio-World, cat#30611183-11 Dublin, OH)  and 1% Penicillin/Streptomycin 
mixture (Life Tecnologies, cat#15070-063 Carlsbad, CA )  Media on the cells were 
changed every 2-3 days and cells are passaged by using 0.05% EDTA trypsin when 
plates were < 90% confluent.  
Protein extraction and Western Blot Analysis 
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Protein from adult tail fibroblasts was extracted by lysis of cell pellets with RIPA buffer 
and protein concentrations are determined by performing a Bradford Assay as per the 
manufacturer's instructions. 100ug protein of each sample was then separated on an SDS-
PAGE gel and transferred to a BioRad membrane (Trans-Blot Turbo: Transfer System) 
using the BioRad western blotting system (BioRad, Hercules, CA). Membranes were 
blocked using 5% milk in 1X TBST for 1 hour and then probed overnight, at 4 degree 
Celsius on a rotator. The following are the primary antibodies at 1:1000 dilutions: Dzip1 
(gift from Stan Hoffman, Medical University of South Carolina, 1: 250), Ift88 (Millipore, 
MA, USA, Cat#ABC932), Tubgcp3 (Millipore, MA, USA, Cat#ABC932) and Glis2 
(Novus Biological, Centennial, CO, USA, Cat# NBP2-41311). The membranes were then 
washed with 1X TBST five times, 10 minutes each and then incubated for 1 hour with 
secondary antibodies at room temperature. The secondary antibody, Anti-Rabbit IgG 
HRP (Abcam, Cambridge, MA, USA, Cat#A9169), was used at 1:10,000 dilution. 
Membranes were then washed again in TBST 5 times, for 10 minutes each. ECL solution 
was then added for 5 minutes (West Femto, Fisher Scientific, Hampton, NH). Signals 




Assemble the following components in a 0.5 ml tube (add the End Conversion Mix last): 
0.5–2.0 µl PCR product (or 2 µl Blunt Vector Control Insert; *see note below) X µl 
Nuclease-free Water to a total of 10 µl 5.0 µl End Conversion Mix 10 µl total volume 
Mix gently by stirring with a pipet tip. * Set up a positive control to test the efficiency of 
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the vector: substitute 2 µl (9 ng = 0.067 pmol) of the Blunt Vector Control Insert 
provided with the kit in place of the amplified product in the above end conversion 
reaction. The Blunt Vector Control Insert is a 212 bp PCR product amplified with Taq 
DNA polymerase. Also prepare a negative control, omitting the PCR product or control 
insert. Incubate the end conversion reaction at 22°C for 15 min. Inactivate the reaction by 
heating at 75°C for 5 min. Note that complete inactivation of the kinase in the End 
Conversion Mix is required to avoid high vector background. Cool the reaction briefly on 
ice (2 min). Please note that the reaction must be chilled prior to proceeding to the 
ligation step to avoid inactivating the ligase. Briefly centrifuge the cooled reaction to 
collect the condensate and proceed to the ligation reaction. Ligation For a standard 
reaction, 1 µl (50 ng) Blunt Vector and 1 µl (4 U) T4 DNA Ligase are added directly to 
the End Conversion reaction, which brings the total volume to 12 µl. To the cooled End 
Conversion reaction, add 1 µl Blunt Vector, and then 1 µl T4 DNA Ligase. Mix gently by 
stirring with the pipet tip used to add the ligase. Incubate at 22°C for 15 min. The molar 
ratio of insert to vector is 2.5:1 under these conditions. This ratio has been shown to 
produce maximum efficiency for ligation to the Blunt Vector Positive Control 212 bp 
insert. Using insert to vector molar ratios from 1:1 to 2.5:1. Treat the positive and 
negative controls set up in the End Conversion step in exactly the same manner as the 
insert-containing sample. Perfectly BluntTM Cloning Kits 8 Novagen TB183 11/99 
United States & Canada 800-207-0144 Germany 0800 6931 000 United Kingdom 0800 
622935 Transformation of NovaBlue Singles™ Competent Cells For transformation, 1 µl 
of the ligation reaction is added directly to NovaBlue Singles Competent Cells. Adding 
higher amounts of the ligation reaction generally will not produce more transformants; 
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more than 2 µl of ligation reaction can dramatically inhibit transformation. Note: Upon 
receipt from Novagen, verify that the competent cells are still frozen and that dry ice is 
still present in the shipping container. Immediately place the competent cells at –70°C or 
below. For optimal results, do not allow the cells to thaw at any time prior to use. Handle 
only the very top of the tube and the tube cap to prevent the cells from warming. Keep 
the cells on ice whenever possible. To mix cells, flick the tube 1–3 times. Do not vortex 
the competent cells. Remove the appropriate number of tubes of NovaBlue Singles 
Competent Cells from the freezer (include one extra sample for the Test Plasmid positive 
control, if desired). Immediately place the tubes on ice, so that all but the cap is 
surrounded by ice. Allow the cells to thaw on ice for ~2–5 min. Visually check the cells 
to see that they have thawed and gently flick the cells 1–2 times to evenly resuspend the 
cells. The cells are then ready for the addition of the ligation reaction. Add 1 µl of a 
ligation reaction or purified plasmid DNA (~1ng/µl) directly to the cells. Stir gently to 
mix and return the tube to the ice, making sure that the tube is surrounded by ice except 
for the cap. Repeat for additional samples. Place tubes on ice for 5 min. Heat the tubes for 
exactly 30 sec in a 42°C water bath; do not shake. Hold the rack in the water bath so that 
the lower halves of the tubes are submerged for 30 sec, and then replace the rack on ice. 
Place on ice for 2 min. 8. Add 250 µl of room temperature SOC Medium to each tube and 
perform the “outgrowth” step (shaking incubation) for 30–60 minutes and shake at 200-






Obtain cVICs/HEK293T from the incubator and count on hemocytometer. For this 
experiment 1X105 cells per well was used. Label well plates accordingly. Plate cells to 
labeled wells. Do not plate more than 2ml of media and cells combined per well. Label 
respective tubes 3.5X cocktails with that include: construct and bgal. Label transfection 
tubes: Add SF Media, Add DNA (cocktail)-respective amount and then Fugene 
(Promega, cat#E2311, Madison,WI) Add 6ul of fugene into Transfection tubes. Wait 15 
min. Examine under microscope. Monitor for 48hr. Then complete luciferase assay.  
 
Co-Immunoprecipitation  
Lysates were obtained from adult tail fibroblasts and 100 μL denaturing lysis buffer was 
added to 0.5–2x107 cells. This was followed by vortexing vigorously for 2–3 sec at 
maximum speed. The cell suspension is then transferred to a microcentrifuge tube and 
samples were heated to 95°C for 5 min to denature the mixture.  The suspension was 
diluted with 0.9 mL non-denaturing lysis buffer and mixed gently. To 
immunoprecipitated the cells add 5 μL of Rb IgG antibody (Invitrogen, Carlsbad, CA 
USA, Cat#ab31235) to 1 mL of lysate then incubate for 1 hr. on ice. Then 25 μL of bead 
slurry was added to the lysate and incubated for 10–30 min at 4°C with gentle agitation 
and spun in microcentrifuge at 14,000 x g at 4°C for 10 min. The bead pellet was 
disregarded and supernatant kept for the immunoprecipitation. 5 µL of primary antibody, 
Prpf8 (Abcam, Cambridge, MA, USA, Cat#ab185547) is added to the supernatant. 
Then incubate the lysate-bead/antibody conjugate mixture at 4°C under rotary agitation 
overnight. At the end of the incubation, wash steps (5X10min) were given. Centrifuge the 
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tubes, remove the supernatant from the beads and discard. Wash the beads with washing 
buffer or lysis buffer three times to remove non-specific binding. For each wash, mix the 
beads gently with wash buffer, centrifuge at 4°C and discard the supernatant. 
 
Luciferase Assay 
Promega Luciferase 100 assays E1500 kit. Prepare Luciferase Assay Reagent (LAR) by 
adding Luciferase Assay Buffer (10ml for E152A and 100ml for E152B) to the vial of 
lyophilized Luciferase Assay Substrate. Dispense into working aliquots and store unused 
LAR at –20°C or –70°C. Before each use of the system, allow LAR to equilibrate to 
room temperature. (Do not thaw LAR at temperatures above 25°C.) Prepare 1X lysis 
reagent by adding 4 volumes of water to 1 volume of 5X lysis reagent (Cell Culture Lysis 
Reagent [CCLR], Cat.# E1531; Reporter Lysis Buffer [RLB], Cat.# E3971. Remove 
growth medium from cultured cells. Rinse cells in 1X PBS. Do not dislodge cells. 
Remove as much of the final wash as possible. Dispense a minimal volume of 1X lysis 
reagent (CCLR, RLB or PLB) into each culture vessel (e.g., 400μl/60mm culture dish, 
900μl/100mm culture dish or 20μl/well for a 96 well plate).For culture dishes, scrape 
attached cells from the dish, and transfer the cells and solution to a microcentrifuge tube. 
Pellet debris by brief centrifugation, and transfer the supernatant to a new tube. Mix 20μl 
of cell lysate with 100μl of Luciferase Assay Reagent and measure the light produced. 
Luciferase assay measured on the Monolight ® 2010, Analytical Luminescence 






RNA Seq analysis 
 
Mitral leaflets were dissected from P0 NfatC1Cre(+); Ift88f/f and P0 NfatC1Cre(+), Ift88+/+. 
Total RNA was isolated using MicroRNeasy (Qiagen). Purity and quantification was 
determined by Bioanalyzer. The library preparation was made using the SMART-Seq®v4 
RNA-seq kit (Clontech Laboratories, Mountain View, CA) following the manufacturer's 
instructions. 
The analysis was carried out on an OnRamp Bioinformatics Genomics Research Platform 
(OnRamp Bioinformatics, San Diego, CA). “OnRamp’s advanced Genomics Analysis 
Engine utilized an automated RNAseq workflow to process the data, including (1) data 
validation and quality control, (2) read alignment to the mouse genome (mm10) using 
STAR RNA-seq aligner, (3) generation of gene-level count data with HTSeq, and (4) 139 
differential expression analysis with DEseq2, which enabled the inference of differential 
signals with robust statistical power (Dobin, Davis et al. 2013, Love, Huber et al. 2014, 
Davis-Turak, Courtney et al. 2017). Transcript count data from DESeq2 analysis of the 
samples were sorted according to their adjusted p-value or q-value, which is the smallest 
false discovery rate (FDR) at which a transcript is called significant. FDR is the expected 
fraction of false positive tests among significant tests and was calculated using the 
Benjamini-Hochberg multiple testing adjustment procedure (Benjamini and Hochberg 
1995). The DE list was then submitted to the iPathway Guide tool from Advaita® 
Bioinformatics which uses a systems biology approach in order to identify pathways that 
are significantly impacted in any condition - from high-throughput gene expression data. 
The impact analysis incorporates the classical probabilistic component of the magnitude 
of the expression changes of each gene, the position of the differentially expressed genes 
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on the given pathways, the topology of the pathway that describes how these genes 
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